

MARKSANS PHARMA LIMITED

Regd. Office:21st Floor Lotus Business Park,Off.Link Road, Andheri [West], Mumbai-400053
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2007(Standalone)

Sr.	PARTICULARS	Quarter ended		Nine month ended		Rs.in Lacs
		31st Dec.07 (UNAUDITED)	31st Dec.06 (UNAUDITED)	31st Dec.07 (UNAUDITED)	31st Dec.06 (UNAUDITED)	Previous Year ended 31st March 07 (AUDITED)
1	Net sales /Income from Operations	5,814.09	7,225.46	16,019.00	21,410.00	23,988.74
2	Other Income	178.41	235.29	574.83	880.16	1,050.29
3	Total Expenditure	4,653.58	6,223.04	13,538.57	18,556.20	22,200.74
	-(Increase) /Decrease in Stock in trade	(934.21)	(247.66)	(1,530.26)	(892.51)	(4,067.93)
	-Consumption of Raw Material	4,889.46	5,269.48	11,394.14	15,844.21	20,278.35
	-Staff Cost	380.37	289.46	1,121.50	806.79	1,375.71
	-Other Expenditure	317.95	911.76	2,553.19	2,797.71	4,614.62
4	Interest	309.71	288.91	1,008.58	816.50	1,149.80
5	Depreciation	225.44	216.46	630.70	753.09	732.32
6	Profit/(Loss) before Tax	803.77	732.34	1,415.98	2,164.37	956.17
7	Provision for Taxation	102.76	127.09	138.45	397.09	421.98
8	Net Profit /(Loss)	701.01	605.25	1,277.53	1,767.28	534.18
9	Add/Less :Short/Excess provision/ Prior period expenses	-	-	-	-	158.41
10	Net Profit/(Loss) after extra ordinary items	701.01	605.25	1,277.53	1,767.28	692.59
11	Paid up Equity Share Capital (Face value Rs. 10 per share)	3,594.06	3,594.06	3,594.06	3,594.06	3,594.06
12	Reserves and Surplus (Excluding Revaluation Reserve)	-	-	-	-	-
13	Basic and Diluted EPS for the period (Not annualised)	1.95	1.68	3.55	4.92	1.93
14	Non -Promoter share holding	-	-	-	-	-
	-Number of Shares	17,962,212	18,776,527	17,962,212	18,776,527	18776527
	-Percentage of Share holding	49.98%	52.24%	49.98%	52.24%	52.24%

Notes:

- The above results have been reviewed by the Audit Committee and thereafter the Board of Directors have taken it on record at the board meeting held on 25th January 2008.
- The details of investor complaints during the quarter is as under:
Opening Balance : NIL, Received during the quarter :NIL, Pending as on 31.12.07 : NIL
- The company will consider the effect of deferred tax asset/liability (AS- 22) in the audited accounts at the year end.
- Information on Consolidated Figures for the Nine Month ended (i)Turnover : Rs 16,557.49 Lacs (ii) PAT: Rs.1376.36 Lacs (iii) EPS: Rs.3.72 Basic
- The Company has completed acquisition of 100% of the share capital of Hale Group Limited,the parent company of Bell, Sons & Co (Druggists) Limited,U.K.. Bell' is a well established and highly reputed manufacturer and marketer of over the counter("OTC") pharmaceuticals products, has full approval of U.K. Medicines and Healthcare Regulatory Agency ("MHRA") and currently holds 34 approved product licenses.Bell's is a profitable Company with high growth outlook and the same will be accretive to the Company's earning from the date of acquisition.
- The above standalone and consolidated financials doesn't includes financials of Hale Group Limited and its subsidiary.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

For MARKSANS PHARMA LIMITED

Place: Mumbai

Date: 25th January 2008

MARK SALDANHA
Managing Director